Sign In

Joshua Disbrow

Co-Founder / Chairman / CEO of Aytu BioScience, Inc. (NASDAQ: AYTU)

Joshua Disbrow is a seasoned entrepreneur and executive in the life sciences industry, currently leading Aytu BioScience in its journey to become a top-tier specialty pharmaceutical company.

With a strong background in commercial success, capital markets, and commercial scaling, Joshua has a proven track record of taking companies from inception to profitability, driving revenue growth, and overseeing the formation and launch of innovative life science ventures.

His expertise spans a wide range of areas including growing sales in the U.S. and internationally, establishing corporate and commercial infrastructures, leading cross-functional teams, and expanding businesses across various clinical markets such as urology, pediatrics, allergy, asthma, cardiovascular disease, neurology, primary care, and psychiatry.

Joshua brings extensive transactional and capital markets experience, having raised over $100M, notably through the successful Aytu BioScience NASDAQ IPO in October 2017.

He also holds an MBA in Management from Wake Forest University School of Business and dual BS degrees in Management from North Carolina State University's College of Management.

In addition to his current role at Aytu BioScience, Joshua has held key positions in other prominent organizations including serving on the Board of Directors at Zynex Medical, acting as Chairman & CEO at Aytu BioScience, functioning as COO of Ampio Pharmaceuticals, where he was also CEO of subsidiary Luoxis Diagnostics, as well as holding executive roles at Arbor Pharmaceuticals, LivaNova, LipoScience, and GlaxoSmithKline.

Joshua Disbrow
Add to my network

Location

Denver, Colorado